Francois X. Claret received his PhD from the University of Lausanne, Switzerland and did his postdoctoral training at the University of California San Diego studying JNK/MAP Kinase cell signaling. He is currently an Associate Professor at MD Anderson and his research focus is on understanding the molecular basis of cancer, especially identifying the cell signaling that leads to oncogene activation and cell cycle dysregulation. He has published over 70 papers and he has been serving as an Associate Editor of the Frontiers in Cancer Molecular Targets and Therapeutics - FrontiersIn and on the editorial board of PLoS ONE.

Translational oncolo gy research • C ell signaling • Targeted therapies • Cell cycle control • DNA damage • microRNAs profiling DNA Methylation • CRISPR/Cas9 • Proteom ics • Animal models of cancer • O ncogene and tumor suppr essor gene s • Targeted therapies • Drug resistance • Trastuzumab/Herceptin • R esistance to targeted therapy • Breast , O varian , H epatocellular carcinoma and Head & Neck cancer s • Lymphoma • S trategies for translating basic science findings into treatments with a clinical impact.